Rocio Martin Hoyos, M.S., M.B.A., joined Kronos Bio in January 2021 and serves as Senior Vice President, Corporate Strategy and Portfolio Management, where she has primary responsibility for portfolio management, alongside financial planning, corporate development and investor relations. Rocio’s insights have played a crucial role in Kronos Bio’s portfolio expansion and management, and she has spearheaded the KB-0742 core team and orchestrated the strategic direction for Kronos Bio’s molecules.

Prior to her tenure at Kronos Bio, Rocio’s vision and leadership were honed at Audentes Therapeutics as VP of Global and US Marketing. There, she established the marketing function and directed the global commercialization strategy for AT132, a pioneering gene therapy, prior to the acquisition by Astellas. Her tenure at Ultragenyx as Global Commercial Lead saw her navigating multiple therapies for rare diseases, demonstrating her exceptional capability in handling complex therapeutic portfolios. Rocio’s foundational experience in hematology and oncology was shaped at Celgene, where she took on roles of increasing responsibility, managing pipeline therapies and commercial products across diverse indications at both EMEA and global levels.

Rocio began her career as an investment analyst at Ysios Capital Partners. She holds a Master of Science in biochemistry from Universidad Autonoma de Madrid and an M.B.A. from IESE Business School in Barcelona. Under Rocio’s leadership of Kronos Bio’s strategic initiatives, the company is well-positioned to navigate the biotech landscape, driving efficiency and innovation in a competitive market.